Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
4h
If you experience these symptoms repeatedly, you could have lung cancer: “You should see a doctor”
A health campaign urges the public to pay closer attention to subtle warning signs that often go unnoticed in the earliest ...
Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...
Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...
Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast Track ...
Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.
Gilead has reported that its phase 3 ASCENT-07 trial evaluating Trodelvy (sacituzumab govitecan-hziy) as a first-line ...
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene therapy ...
A new study published in the journal of BMC Psychiatry showed that adults diagnosed with depression before the age of 16 had ...
Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback